Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

193
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
193
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

246
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
246
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

361
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
361
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

297
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
297
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

823
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
823
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

164
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of hospital length of stay, discharge disposition, and readmission after craniopharyngioma surgery: a multicenter study from the RAPID database.

Neurosurgical focus·2026
Same author

The present and the future of risk stratification for and prevention of sudden cardiac death: A Heart Rhythm Society think tank meeting.

Heart rhythm·2026
Same author

Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use: Systematic Review of Synthetic Progestins and Case Series of DMPA-Associated Intracranial Meningiomas.

Neurosurgery·2026
Same author

Application of Mixed Reality in Endoscopic Streaming During Skull Base Surgery.

Operative neurosurgery (Hagerstown, Md.)·2026
Same author

Current Utilizations and Limitations of Augmented Reality in Otolaryngology-Head and Neck Surgery: A Scoping Review.

The Annals of otology, rhinology, and laryngology·2026
Same author

Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study.

JACC. Advances·2026
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K

Future research prioritization in cardiac resynchronization therapy.

Marat Fudim1, Frederik Dalgaard2, Sana M Al-Khatib3

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC.

American Heart Journal
|March 13, 2020
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) research needs further investigation for heart failure patients. Key evidence gaps include comorbidities, atrial fibrillation, and patient subgroups to optimize CRT effectiveness.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Related Experiment Videos

Last Updated: Dec 26, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Research

Background:

  • Cardiac resynchronization therapy (CRT) benefits select patients with heart failure and reduced ejection fraction (HFrEF).
  • Significant evidence gaps persist regarding CRT's clinical and policy implications.

Purpose of the Study:

  • To review existing data on CRT for HFrEF patients on pharmacological therapy, with or without an implantable cardioverter-defibrillator (ICD).
  • To identify and prioritize evidence gaps through stakeholder consensus, developing a future research agenda.

Main Methods:

  • Systematic literature search of PubMed, EMBASE, and clinicaltrials.gov.
  • Stakeholder-driven forced-ranking prioritization to identify and rank critical evidence gaps.
  • Inclusion of diverse stakeholders: investigators, patients, public, industry, and policymakers.

Main Results:

  • Identified 18 top-tier evidence gaps concerning CRT in HFrEF.
  • Key gaps focus on specific populations (8), comparative effectiveness/safety (7), and treatment outcomes (3).
  • Highest-ranked gaps involve comorbidities, atrial fibrillation, and CRT/ICD effectiveness by gender and QRS characteristics.

Conclusions:

  • This review highlights critical, unresolved clinical and policy questions regarding CRT in HFrEF.
  • The identified gaps provide a roadmap for future collaborative research to advance CRT understanding and application.